Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following Intravenous or Oral Inhaled Administration to Healthy Adult Subjects
Authors:
Open Access
- 1 November 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (11) , 5178-5184
Abstract
Zanamivir serum and pulmonary pharmacokinetics were characterized following intravenous (i.v.) or oral inhaled administration. I.v. zanamivir was given as intermittent doses of 100 mg, 200 mg, and 600 mg every 12 h (q12h) for two doses or as a continuous infusion (6-mg loading dose followed by 3 mg/h for 12 h). Oral inhaled zanamivir (two 5-mg inhalations q12h for two doses) was evaluated as well. Each zanamivir regimen was administered to six healthy subjects with serial pharmacokinetic sampling. In addition, a single bronchoalveolar lavage (BAL) fluid sample was collected at various time points and used to calculate epithelial lining fluid (ELF) drug concentrations for each subject. For intermittent i.v. administration of 100 mg, 200 mg, and 600 mg zanamivir, the median zanamivir concentrations in ELF collected 12 h after dosing were 74, 146, and 419 ng/ml, respectively, each higher than the historic mean 50% inhibitory concentrations for the neuraminidases of wild-type strains of influenza A and B viruses. Median ELF/serum zanamivir concentration ratios ranged from 55 to 79% for intermittent i.v. administration (when sampled 12 h after the last dose) and 43 to 45% for continuous infusion (when sampled 6 to 12 h after the start of the infusion). For oral inhaled zanamivir, the median zanamivir concentrations in ELF were 891 ng/ml for the first BAL fluid collection and 326 ng/ml for subsequent BAL fluid collections (when sampled 12 h after the last dose); corresponding serum drug concentrations were undetectable. This study demonstrates zanamivir's penetration into the human pulmonary compartment and supports the doses selected for the continuing development of i.v. zanamivir in clinical studies of influenza.Keywords
This publication has 17 references indexed in Scilit:
- Recovery of a Multidrug‐Resistant Strain of Pandemic Influenza A 2009 (H1N1) Virus Carrying a Dual H275Y/I223R Mutation from a Child after Prolonged Treatment with OseltamivirClinical Infectious Diseases, 2010
- Emergence of a Multidrug-Resistant Pandemic Influenza A (H1N1) VirusNew England Journal of Medicine, 2010
- Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) VirusClinical Infectious Diseases, 2010
- Intravenous Zanamivir for Patients with Pneumonitis due to Pandemic (H1N1) 2009 Influenza VirusClinical Infectious Diseases, 2010
- Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 InfluenzaNew England Journal of Medicine, 2010
- Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaquesAntiviral Research, 2008
- Oseltamivir Resistance during Treatment of Influenza A (H5N1) InfectionNew England Journal of Medicine, 2005
- Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjectsJournal of Antimicrobial Chemotherapy, 2003
- Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and OseltamivirAntimicrobial Agents and Chemotherapy, 2003
- Anatomical distribution of bronchoalveolar lavage fluid as assessed by digital subtraction radiography.Thorax, 1987